Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 20/100

ADMA FRAUD NOTICE: Lost Money on Your ADMA Biologics, Inc. Securities? Contact BFA Law about its Investigation into the Company after Auditor Resigns (Nasdaq:ADMA)

Key Takeaway: ADMA Biologics, Inc. is under investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws following the resignation of its independent auditor, CohnReznick LLP. This unexpected event has triggered a severe decline in the company's stock price, dropping over 20% shortly after the announcement. Investors in ADMA Biologics are encouraged to seek legal advice regarding possible damages due to this situation. The law firm’s investigation highlights serious concerns about the company’s financial practices and investor protection.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics experienced a significant stock drop of over 20% following the resignation of its auditor.
  • The investigation by BFA Law into potential violations of federal securities laws raises concerns about the company's governance.
  • Investors may face financial losses as a result of these developments, leading to calls for legal action.

Full Press Release Details

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What triggered the stock drop for ADMA Biologics?

The stock dropped after ADMA Biologics announced the unexpected resignation of its auditor, CohnReznick LLP.

By how much did ADMA Biologics's stock decline?

ADMA Biologics's stock fell over 20% during trading on October 10, 2024.

What legal options are available for ADMA investors?

Investors in ADMA Biologics may have legal options and can submit their information to the firm.

Why choose Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a top law firm known for successful securities class actions.

Last updated: Oct 17, 2024